The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESH 2017 | The molecular mechanisms of epigenetic therapies: LTRs and TINATs
As the finer details of how therapies interact within the body become clear, novel research to create more effective medications can occur. At the International Conference on Acute Myeloid Leukaemia 2017 in Estoril, Portugal by the European School of Haematology (ESH), Christoph Plass, PhD, from the German Cancer Research Center, Heidelberg, Germany, discusses the use of epigenetic therapies to tackle acute myeloid leukemia and myelodysplastic syndromes. Dr Plass highlights the potential molecular mechanisms that these drugs utilize to promote the apoptosis of leukemic cells, referencing LTRs and treatment-induced non-annotated TSSs.
